Anzeige
Mehr »
Login
Sonntag, 05.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Cannabisaktien sollten nun den S&P um 60% outperformen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
69 Leser
Artikel bewerten:
(0)

Jeffrey Epstein, Science Investor, Applauds Key Discoveries Into Late Onset Alzheimer's

NEW YORK, May 29, 2013 /PRNewswire/ --Although there are genetic dispositions for Alzheimer's Disease, the late onset of Alzheimer's and by far the most common, is still a mystery. It's also expected to double by 2050. Today however, renowned New York science investor,Jeffrey Epstein, whose foundation has provided funds to theAmerican Alzheimer's Association, has heralded new findings into the late onset disease.

The findings come from Mount Sinai Hospital in New York, the Icelandic Heart Association andSage Bionetworks, amongst others, who have determined that a cluster of genes connected to the brain's inflammatory response mechanism, play a role in driving late onset Alzheimer's. Specifically, the research team analyzed the DNA of 376 deceased patients with late Alzheimer's along with gene expression and emanating biological pathways. What resulted was a mathematical model, a unified map of the prevailing genes present in late Alzheimer's and the pathways that they trigger.

One such gene, TYROBP, not typically connected to Alzheimer's but linked to brain inflammation, was shown to interact with TREM2, a gene recently connected to Alzheimer's.

The discovery is critical,Dr. Bin Zhangexplained, a co-author of the study and Associate Professor of Genetics and Genomic Sciences at Mount Sinai. "We can now evaluate drugs that impact the TREM2-TYROBP pathway as potential therapies and design more specific compounds that target these key steps precisely, in contrast to existing anti-inflammatory drugs that may be less ideal for hitting this target."

"The use of mathematics to understand the causes of disease is an exciting new field," Jeffrey Epstein asserted. "One can detect patterns that are otherwise hidden and target therapies more precisely."

Jeffrey Epstein is not new to mathematics in medical research. In 2003, he founded the Program for Evolutionary Dynamics at Harvard University, which studies the evolution of micro-biology with the use of mathematics. The Program has also made critical discoveries into the evolution of cancer, HIV and other viruses.

Jeffrey Epstein is a former member of the New York Academy of Science and Rockefeller University. He sits on the Mind, Brain & Behavior Advisory Committee at Harvard University.

SOURCE Jeffrey Epstein VI Foundation

Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2013 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.